2-HOBA Supplementation in People With Elevated Lipoprotein(a)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-69
SponsorThe Miriam Hospital
About this trial
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.
The main questions it aims to answer are:
Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood?
Participants will:
Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Males and females aged 18-69 years.
Elevated Lp(a) levels ≥ 90 mg/dL.
Able to provide informed consent and adhere to study schedules.
Willing to follow a physician-recommended diet during the study.
Disqualifiers
Pregnant, planning pregnancy during the study period, or currently breastfeeding.
Individuals with established cardiovascular disease
Planning major changes in diet or exercise routines.
Experienced >20% weight change in the past 3 months.
Trial design
Design model
Single group
Treatments tested in this trial
2-HOBA (Hobamine)
Dietary supplementParticipants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.
Treatment groups
10 Participants
are divided into 1 treatment groupGroup A: 2-HOBA Supplementation for Elevated Lipoprotein(a)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in oxidized phospholipids (OxPL) on circulating lipoprotein(a)
OxPL levels on circulating lipoprotein(a) will be measured in blood samples collected before and after 6 weeks of oral 2-HOBA supplementation.
Time frame
6 weeksSecondary outcomes
1
High-sensitivity CRP
High-sensitivity CRP will be measured in blood samples to assess changes in systemic inflammation after 2-HOBA supplementation.
Time frame
6 weeks2
Interleukin-6
IL-6 levels will be measured in plasma to evaluate the effect of 2-HOBA on inflammatory signaling.
Time frame
6 weeks3
Tumor Necrosis Factor-alpha (TNF-α)
TNF-α concentrations will be measured in plasma as an additional marker of inflammation.
Time frame
6 weeks4
Fibrinogen
Plasma fibrinogen levels will be measured to assess changes in blood clotting potential.
Time frame
6 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: